The University of Texas MD Anderson Cancer Center is the latest Houston hospital to come under federal investigation after reporting an “adverse event” involving a blood transfusion in December, 2018 to the FDA reports Olivia Pulsinelli of the Houston Business Journal.
The FDA referred the matter to the Centers for Medicare and Medicaid Services (CMS) which subsequently reported on “serious deficiencies.” The Houston Chronicle broke the story and in fact shared that in the federal letter it declared “These deficiencies have been determined to be of such a serious nature as to substantially limit your hospital’s capacity to render adequate care” the Chronicle quotes one of the letters as staying.
We are not sure whether the adverse event resulted in a patient death, but MD Anderson told the Chronicle that it did not involve mislabeling. The hospital expects to submit a plan of corrective action next week.
MD Anderson is on record stating “We have policies and procedures in place to protect our patients,” reported a MS Anderson official in an email to the Chronicle. “However, in rare instances, severe reactions occur. The transfusion of blood and blood products from human to human carries inherent risks—from mild to severe.”
Apparently, MD Anderson remains a CMS participant but according to the Houston Business Journal the prestigious research center is under federal and state authority until it regains CMS compliance.
Baylor St. Luke’s Medical Center Also Under Pressure
Texas Medical Center, Baylor Luke’s Medical Center was also investigated within the past several months for a blood transfusion incident. But the hospital has been under scrutiny for roughly a year. In May 2018 the Chronicle and ProPublic published a report detailing how the hospital’s famed heart transplant program had been seeing worse than expected outcomes in recent years. Due to ongoing problems Baylor St. Luke’s lost its eligibility for Medicare funding in August 2018.
TrialSite News will monitor the MD Anderson situation.